0 XP 0   0   0  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Sonnet Biotherapeutics Holdings Inc - Trending symbols

Latest News of Sonnet Biotherapeutics Holdings Inc

DateTitleRead
2025-01-28
15:05
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform TechnologyRead
2025-01-22
14:35
Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment WebinarRead
2025-01-21
15:05
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain SarcomasRead



Trends

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Total Operating Expenses 3,637-2,3601,2782,5713,848-3193,529-4,894-1,365
Income before Tax -5,6671,720-3,947270-3,6772,508-1,1691,534365
Net Income -5,6721,725-3,947270-3,6772,508-1,1691,534365
Net Income from Continuing Operations -5,6671,720-3,947270-3,6772,508-1,1691,534365
Gross Profit 19-118018018-19-1
Depreciation and Amortization 25-1249334376-128-52
Total Stockholder Equity 22,260-5,86916,391-7,8588,533-7,769764-3,303-2,539
Net Working Capital 22,108-5,86916,239-7,8368,403-7,739664-3,415-2,751
Net Invested Capital 22,261-5,86916,392-7,8588,534-7,769765-3,303-2,538

Comments

How you think about this?

Leave a comment

Stay informed about Sonnet Biotherapeutics Holdings Inc.

Receive notifications about Sonnet Biotherapeutics Holdings Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.